Donat Margaret, Odiase Ivie, Alleva Aldo, Bissoonauth Aditya A, Khan Hamnah, Siddiqui Sara
Department of Family Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Long Island, New York, United States.
Family Medicine Service Line, Northwell Health, Long Island, NY, United States.
J Family Med Prim Care. 2025 May;14(5):2070-2073. doi: 10.4103/jfmpc.jfmpc_504_24. Epub 2025 May 31.
Guillain-Barré syndrome (GBS) is an inflammatory disease of the peripheral nervous system, with Miller-Fisher syndrome (MFS) being a rare variant. Recent studies have shown GBS and MFS to be a common side effect of COVID-19. This case report highlights the clinical presentation of a patient diagnosed with post-COVID-19 MFS, their subsequent treatment challenges, and the prognostic outcomes, contributing to the limited scientific literature of this uncommon affliction. A comprehensive case report of a 57-year-old man with significant medical history was conducted to determine the appropriate diagnosis based on the perceived symptoms following COVID-19. Per the Northwell health human research protection program, the publication of case reports involving up to three patients is not considered human-subject research and does not require IRB review and approval. Our patient was diagnosed with MFS, making him the longest-known adult with COVID-19-associated MFS without resolution of neurologic symptoms after intravenous immunoglobulin (IVIG) dose administration. Our case report posits the first-known patient to have a more severe form of MFS or resistance to IVIG dose. The current study also highlights the association between COVID-19 and MFS, warranting the need for more studies to understand the disease pathophysiology and new biomarkers for targeted treatments.
吉兰-巴雷综合征（GBS）是一种周围神经系统的炎症性疾病，米勒-费希尔综合征（MFS）是其罕见变体。最近的研究表明，GBS和MFS是新冠病毒病（COVID-19）的常见副作用。本病例报告突出了一名被诊断为COVID-19后MFS患者的临床表现、随后的治疗挑战以及预后结果，为这种罕见疾病的有限科学文献提供了补充。对一名有重要病史的57岁男性进行了全面的病例报告，以根据COVID-19后的感知症状确定适当的诊断。根据诺斯韦尔健康人体研究保护计划，发表涉及至多三名患者的病例报告不被视为人体研究，不需要机构审查委员会（IRB）的审查和批准。我们的患者被诊断为MFS，使其成为已知感染COVID-19相关MFS且在静脉注射免疫球蛋白（IVIG）给药后神经症状未缓解的最长病程成年患者。我们的病例报告提出，该患者是已知首例患有更严重形式的MFS或对IVIG剂量耐药的患者。当前研究还突出了COVID-19与MFS之间的关联，这表明需要更多研究来了解疾病病理生理学以及用于靶向治疗的新生物标志物。
